Home Cart Sign in  
Chemical Structure| 127191-97-3 Chemical Structure| 127191-97-3

Structure of KN-62
CAS No.: 127191-97-3

Chemical Structure| 127191-97-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KN-62 is a selective and potent inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with IC50 of 0.9 μM, KN-62 also displays noncompetitive antagonism at P2X7 receptors in HEK293 cells, with an IC50 value of approximately 15 nM..

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KN-62

CAS No. :127191-97-3
Formula : C38H35N5O6S2
M.W : 721.84
SMILES Code : O=C(N1CCN(C2=CC=CC=C2)CC1)[C@H](CC3=CC=C(C=C3)OS(=O)(C4=CC=CC5=C4C=CN=C5)=O)N(C)S(=O)(C6=CC=CC7=C6C=CN=C7)=O
MDL No. :MFCD00083180
InChI Key :RJVLFQBBRSMWHX-DHUJRADRSA-N
Pubchem ID :5312126

Safety of KN-62

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CaMKII

    CaMKII, Ki:0.9 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Human lymphocytes 12.7 nM (IC50) 5 minutes Inhibition of ATP-stimulated Ba2+ influx Br J Pharmacol. 1997 Apr;120(8):1483-90.
Human B-lymphocytes 1 µM 5 min Inhibited ATP-induced 86Rb+ efflux by 96.0% Br J Pharmacol. 2004 Jul;142(6):1015-9.
HP cells (HEK-293 cells stably transfected with rat PROT cDNA) 25 µM 1 hour KN-62 (CaMK II inhibitor) stimulates PRO uptake and abolishes thapsigargin inhibition, indicating PROT regulation by CaMK II. Br J Pharmacol. 2000 Feb;129(3):465-70.
HP cells (HEK-293 cells stably transfected with rat PROT cDNA) 25 µM 1 hour KN-62 (a CaMK II inhibitor) stimulates PRO uptake and abolishes the thapsigargin inhibitory effect, indicating that PROT is regulated by CaMK II. Br J Pharmacol. 2000 Feb;129(3):465-70.
PBMCs 1 µM 24 hours To evaluate the effect of KN-62 on BzATP-inhibited IL-21 production by cTfh cells. KN-62 partially rescued the IL-21 production by cTfh cells. Front Immunol. 2024 Jul 9;15:1397098.
PBMCs 1 µM 24 hours To evaluate the effect of KN-62 on BzATP-induced apoptosis of cTfh cells. KN-62 mitigated the apoptosis of cTfh cells induced by BzATP. Front Immunol. 2024 Jul 9;15:1397098.
PBMCs 1 µM 3 days To evaluate the effect of KN-62 on BzATP-inhibited proliferation of cTfh cells. KN-62 partially rescued the proliferative response of cTfh cells. Front Immunol. 2024 Jul 9;15:1397098.
GT1-7 cells 10 µM 30 min KN-62 prevented the histamine-induced desensitization of calcium signals in GT1-7 cells, indicating a crucial role for calcium/calmodulin-dependent protein kinase II (CaMKII) in histamine H1 receptor desensitization. Br J Pharmacol. 1996 Jul;118(5):1119-26.
Adult skeletal muscle fibers 5 µM 30 minutes KN-62 completely blocked the translocation of HDAC4-GFP from the nucleus to the cytoplasm induced by 10 Hz electrical stimulation J Cell Biol. 2005 Mar 14;168(6):887-97.
HEK293 cells 86 nM (IC50) 4 min KN-62 potently inhibited rmP2X7 receptor-mediated currents with an IC50 of 86 nM, and the inhibition was largely irreversible Br J Pharmacol. 2011 Sep;164(2b):743-54.
Rat atria 10 µM 45 minutes To investigate the effect of KN-62 on stimulation-induced noradrenaline synthesis, results showed that KN-62 did not affect S-I [3H]-noradrenaline synthesis. Br J Pharmacol. 1996 Dec;119(8):1605-13.
HeLa-mPanx1 cells 10 µM 5 minutes To evaluate the effect of CaMKII inhibition on Poly(I:C)-induced Panx1 HC activity. KN-62 preincubation completely prevented the Poly(I:C)-induced increase in DAPI uptake. Theranostics. 2025 Jan 20;15(6):2470-2486.
Human lymphocytes 31.5 nM (IC50) 5 minutes Inhibition of ATP-stimulated L-selectin shedding Br J Pharmacol. 1997 Apr;120(8):1483-90.
Human lymphocytes 5.9 nM (IC50) 5 minutes Inhibition of ATP-stimulated phospholipase D activity Br J Pharmacol. 1997 Apr;120(8):1483-90.
Human lymphocytes 13.1 nM (IC50) 5 minutes Inhibition of ATP-stimulated ethidium+ uptake Br J Pharmacol. 1997 Apr;120(8):1483-90.
RAW264.7 cells 10 µM 6 hours To evaluate the effect of CaMKII inhibition on Poly(I:C)-induced inflammatory response. KN-62 preincubation prevented the upregulation of IL-1β and TNF-α mRNA levels induced by Poly(I:C). Theranostics. 2025 Jan 20;15(6):2470-2486.
Rat ventricular myocytes 10 µM To investigate the inhibitory effect of KN-62 on IKATP augmented by hypoxia and GSSG. The results showed that KN-62 inhibited the IKATP augmented by hypoxia and GSSG, suggesting that the effects of both GSSG and hypoxia on KATP channels involve the activation of the CaMK II pathway. Acta Pharmacol Sin. 2009 Oct;30(10):1399-414.
HEK-293 cells up to 3 µM To test the inhibitory effect of KN-62 on mouse, human, and rat P2X4 receptors, showing no concentration-dependent inhibition at any of the receptors Br J Pharmacol. 2000 Jan;129(2):388-94.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rat Isolated rat heart ischemia/reperfusion injury model Perfusion 3 μM 1 min before and 3 min throughout the Ca2+-free solution perfusion, as well as 3 min after restoring normal KH solution KN-62 alleviated heart injury and calpain activity, and attenuated the binding of CAPN1 to phospho-CaMKII Cell Death Dis. 2020 May 21;11(5):388

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.93mL

1.39mL

0.69mL

13.85mL

2.77mL

1.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories